Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04078399
Other study ID # SHSYXY- aza-relapse-2019002
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 28, 2019
Est. completion date August 28, 2022

Study information

Verified date October 2020
Source Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact Xianmin Song, M.D
Phone 021-63240090
Email shongxm@139.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-center, one-arm, prospective, phase II clinical trial with the primary objective of assessing the effectiveness of azacitidine combined with interferon in the prevention of recurrence after allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system. Sex and safety. At the screening/baseline period, informed consent is obtained and the inclusion/exclusion criteria are checked. Plan to enroll 30 patients, and collect demographic data, medical history data, vital signs, physical examination, laboratory tests (hematuria, liver and kidney function; immune indicators: T cell subsets, Treg, etc.), pregnancy test for female patients And other necessary auxiliary inspections. The time to start treatment is: a decrease in chimerism and/or minimal residual disease (MRD) after myeloid tumor allogeneic hematopoietic stem cell transplantation.


Description:

Treatment programs: 1. Basic protocol: Azacitidine is administered subcutaneously at 32 mg/m2/d for 5 consecutive days; α-interferon treatment started on day 8 for 3 weeks; 4-6 weeks/treatment with long-acting interferon Gebin). 1-1.5 million U / kg, once a week; or ordinary alpha-interferon, 200 acres / square meter / d (total ≥ 300MU / d), 5-7 days a week; 2. Start time of medication: 1 In the absence of immunosuppressive agents such as cyclosporine, the chimeric rate is decreased and/or MRD-positive: or in the case of immunosuppressive agents such as cyclosporine, the chimeric rate is fully chimeric and MRD-positive: A-interferon is first administered. Single-agent intervention, if there was no significant decrease in MRD for 2 consecutive courses (MRD decreased ≤ 50%), azacitidine combined with interferon intervention was started; 2 In the case of calmodulin immunosuppressant (cyclosporine or tacrolimus), the chimeric rate decreased and the MRD was negative, the immunosuppressant was rapidly reduced or discontinued, and the bone marrow was reviewed 2 weeks, if the chimeric rate did not rise. (decreased or stable), or after two consecutive immunosuppressive adjustments did not reach complete chimerism, start azacitidine combined with interferon intervention; (3) If cyclosporine or other immunosuppressive agents are applied before the start of the study, rapid reduction; dose reduction 1 / 4-1 / 2; if the chimeric rate increases or GVHD occurs, continue the immunosuppressant adjustment strategy; (4) Stop treatment: acute GVHD above II degree; patients are intolerant to the study protocol; basic regimen is ineffective after 2 courses of treatment (chimeric rate continues to decline or MRD continues to increase) or disease recurrence; transplant.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 28, 2022
Est. primary completion date August 28, 2022
Accepts healthy volunteers No
Gender All
Age group 14 Years and older
Eligibility Inclusion criteria: Patients enrolled must meet the following criteria: 1. = 14 years old, male or female; 2. Patients with allogeneic peripheral blood stem cell transplantation due to myeloid tumors of the blood system (AML/MDS/CML/MPN, etc.); 3. Recurrence trend evaluation criteria: the proportion of bone marrow blast cells <5%; flow cell MRD = 0.01% and interval 2 consecutive times 2 times; fusion gene interval 2 weeks at least 2 consecutive positive and rising trend or from negative to positive; Bone marrow WT1 levels increased dynamically and were greater than 0.6%; chimeric rate (STR) decreased by >5% (STR <90%) or XY-FISH donor chimerism decreased by >0.5%; 4. Blood routine: neutrophils>0.5×109/L, platelets>25.0×109/L; 5. There is no active grade II or higher acute GVHD or moderate or severe chronic GVHD; 6. Liver and kidney function: liver function (AST/ALT/TB) <5 times normal upper limit; renal function (Cr) < 2 times normal upper limit; 7. The patient must be able to understand and be willing to participate in the study and sign an informed consent form. Exclusion criteria: Possible subjects who meet any of the following criteria will be excluded from the trial: 1. Recurrence after transplantation; 2. Patients who have not achieved complete remission after transplantation; 3. Implantation failed; 4. Pregnant or lactating women; 5. Have received other interventions or are receiving other research drugs before the study begins; 6. Patient blood routine: ANC <0.5 × 109 / L or PLT < 25 × 109 / L; 7. There are active uncontrolled infections: hemodynamic instability associated with infection, or new signs or signs of infection, or new infections in imaging, persistent fever with asympto or signs cannot be ruled out Infected person 8. People infected with HIV; 9. Active hepatitis B (HBV), active hepatitis C (HCV) requires antiviral therapy; patients with HBV activation risk refer to patients with hepatitis B surface antigen positive or core antibody positive patients who do not receive anti-HBV treatment; 10. Those who are allergic to known azacitidine or interferon; 11. At the discretion of the investigator, other dangerous complications may result.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azacitidine combined with interferon preemptive treatment
Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system

Locations

Country Name City State
China Xianmin Song Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment response rate Treatment response rate after 6 months of pretreatment with azacitidine combined with interferon (primary response + secondary response) 6months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Not yet recruiting NCT05532111 - Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial N/A
Active, not recruiting NCT04284215 - Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC N/A
Completed NCT06202456 - A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver Phase 4
Completed NCT04870606 - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Phase 3
Completed NCT03660761 - Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors Phase 2
Active, not recruiting NCT03794778 - Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Phase 4
Recruiting NCT03255343 - Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim N/A
Recruiting NCT04197544 - Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study. N/A
Recruiting NCT04518501 - Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer Phase 1/Phase 2
Completed NCT03779776 - The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants N/A
Not yet recruiting NCT06218004 - Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma Phase 2
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Active, not recruiting NCT06194188 - A Phase 2 Clinical Study of CU-20401 Phase 2
Recruiting NCT03901235 - MSC Intratissular Injection in Crohn Disease Patients Phase 1/Phase 2
Completed NCT03826004 - Clemastine in Cardiovascular Surgery N/A
Active, not recruiting NCT03623776 - Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. Phase 2
Not yet recruiting NCT06351735 - Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
Not yet recruiting NCT06383078 - HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer Phase 2
Withdrawn NCT05481775 - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Phase 2